Contact Us
Drug Search Results
More Filters [+]

Lipegfilgrastim

Alternative Names: lipegfilgrastim
Latest Update: 2024-05-14
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: G-CSF

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lipegfilgrastim

Countries in Clinic: New Zealand, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Hepatitis B, Chronic|Intestinal Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2006-7041-83/hah

P2

Not yet recruiting

Intestinal Diseases|Hepatitis B, Chronic

None

Recent News Events

Date

Type

Title

05/14/2024

PubMed

 Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.

04/30/2024

PubMed

 Dimethyl sulfoxide as a gas phase charge-reducing agent for the determination of PEGylated proteins' intact mass.

03/29/2024

PubMed

 Severe Pseudomonas aeruginosa Pneumonia in a Breast Cancer Patient Despite Pegfilgrastim Administration.

01/11/2023

News Article

 G-CSFPEG-G-CSF Market Set to Reach at USD 5,685.40 Million by 2030, Size, Share, Demand, Future Growth and Competitors Outlook

03/11/2022

News Article

 Neutropenia Biologic Drug Treatment Global Market Report 2022

03/03/2022

News Article

 G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022

12/08/2021

News Article

 Neutropenia Biologic Drug Treatment Global Market Research Report 2021 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions